FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

Home
/
update
/
details

Labcorp Completes Acquisition of Select Invitae Assets

NextEdge Admin

05 Aug 2024

1 min 22 sec

Labcorp , a global leader in comprehensive laboratory services, has completed the acquisition of select assets from Invitae , a prominent medical genetics company. This merger aims to enhance patient care, clinician support, and pharmaceutical partnerships across therapy development, patient diagnosis, and personalized care.

"Labcorp and Invitae share a mission to leverage genetic insights to transform medicine, deliver personalized care, and improve health outcomes," stated Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and COO of Labcorp. By integrating Invitae's advanced science and experience, Labcorp will enhance its genetic testing solutions, particularly in oncology and rare diseases. This acquisition strengthens Labcorp's specialty testing capabilities and its use of genetic data to improve clinical trials and treatment strategies. The combined expertise will provide comprehensive patient insights, from testing and diagnosis to treatment, ultimately improving health outcomes.